Chemotherapy Hair Loss: Which Drugs Cause It, What Scalp Cooling Achieves, and the Regrowth Timeline

Who This Is For#

This guide is for you if:

• You are about to start chemotherapy and want to know whether your regimen is likely to cause hair loss
• You are deciding whether to ask your oncology team about scalp cooling
• You have finished chemotherapy and want to know when regrowth starts and what it may look like
• Your hair has not come back many months after treatment
• You are on tamoxifen or an aromatase inhibitor and have noticed gradual thinning

This guide is NOT for you if:

• Your thinning is gradual and unrelated to cancer treatment: see Androgenetic Alopecia: Complete Guide
• Your shedding began a few months after an illness or surgery rather than during chemotherapy: see Telogen Effluvium: Causes and Recovery Timeline
• You have round, smooth bald patches with no drug exposure: see Alopecia Areata: Types, Treatment, and Outlook
• You have scalp pain, redness, or scarring with the hair loss: see When to See a Dermatologist for Hair Loss: Red Flags

Anagen Effluvium: Why Chemotherapy Hair Loss Is Fast#

How anagen effluvium differs from telogen effluvium#

A dermatology review defines it: "Anagen effluvium is the abrupt loss of hairs that are in their growing phase (anagen) due to an event that impairs the mitotic or metabolic activity of hair follicle" [1]. Chemotherapy hits rapidly dividing cells, including the matrix cells of a growing hair, and the weakened shaft snaps. The same review notes that "Anagen effluvium is considered synonymous with chemotherapy-induced alopecia and other causes are rarely considered" [1].

Telogen effluvium works differently. Headington describes it as "a perturbation of the hair cycle that is manifest by increased loss of normal club hairs" [2]: a trigger pushes follicles out of growth early, and the hairs later shed as intact club hairs. Anagen effluvium sheds broken shafts, hits most of the scalp because most hairs are growing at any moment, and is "reversible, and hair regrowth occurs after a delay of 1-3 months" [1].

Both can coexist in a cancer patient: the anagen insult from the drug plus a telogen shift from surgery, anesthesia, or weight loss. If shedding began months after an operation rather than during infusions, start with the telogen effluvium guide and the surgery and illness guide.

Which Drugs Cause the Most Hair Loss#

Taxanes, anthracyclines, and alkylating agents#

A scoping review of breast cancer regimens found that "Anthracycline and taxane-based treatments carried the highest risk, with severe alopecia reported in more than 70% of patients" [3], and that "Cyclophosphamide amplified CIA when combined with doxorubicin (up to 93% incidence), while capecitabine and vinorelbine showed lower rates" [3]. A scoping review pools heterogeneous studies, so treat these as reported ranges, not trial-grade estimates.

A prospective Japanese cohort is cleaner: it followed "68 female Japanese patients with breast cancer (median age 53 years, range 29-76 years) who received perioperative adjuvant chemotherapy with fluorouracil/epirubicin/cyclophosphamide (FEC) and taxane" [4], and "CIA occurred in all patients, with severe hair loss irrespective of age" [4].

The docetaxel prescribing information treats alopecia as expected rather than dose-limiting: "For other greater than grade 3 toxicities, except alopecia and anemia, chemotherapy should be delayed" [5]. If your regimen contains a taxane or an anthracycline, plan on substantial loss; scalp cooling reduces it but does not eliminate it [8]. For other regimens, ask your oncology team what they see with your protocol and dose.

Scalp Cooling: What the Trials Show#

Scalp cooling chills the scalp during and for a period after each infusion; the cohort study maintained scalp temperature "throughout treatment and 90-120 minutes afterward" [7].

The SCALP randomized trial and the Rugo prospective cohort#

The SCALP trial "enrolled 182 women with breast cancer (119 cooling, 63 control)" [6]. Its endpoint was "Successful hair preservation (grade 0-1 on Common Terminology Criteria)" [6], which allows some thinning, and "The interim analysis led to early termination" [6]. Adverse events in the cooling group "were grades 1-2 only, with no serious device-related events" [6].

The companion Rugo prospective cohort "evaluated 122 early-stage breast cancer patients (106 cooling, 16 control) receiving adjuvant or neoadjuvant chemotherapy excluding sequential anthracycline-taxane combinations" [7]. Its endpoint was "Hair loss of 50% or less" [7], and side effects were limited to "headache in 4 patients (3.8%) and 3 discontinuations (2.8%) due to cold sensation" [7]. The two success rates are not directly comparable: the Rugo prospective cohort was non-randomized with only 16 controls, and it excluded sequential anthracycline-taxane regimens, the combination that caused severe loss in all 68 patients of the FEC-plus-taxane cohort [4], whereas SCALP was randomized.

Meta-analyses and predictors of success#

A meta-analysis of "Ten studies comprising 654 patients (66% breast cancer, mostly receiving anthracyclines)" [8] found that "scalp cooling reduced relative risk (RR) of alopecia by 43% (RR, 0.57; 95% CI, 0.45-0.72; I2 = 11%; P < .00001)" [8] for less than versus greater than 50% hair loss; the authors "graded the evidence quality as moderate" [8]. A later review covering 832 participants pooled 9 trials (494 participants) and reached the same 43% reduction, RR 0.57, but with heterogeneity of 63.8% [9], and found "No serious short- or medium-term adverse events related to cooling were documented" [9]. The trials disagree more than one pooled number suggests.

What predicts success? A structured review concluded that "A subcutaneous scalp temperature less than 22 °C is required for hair preservation" [10] and that "Success of scalp cooling varies substantially between patients and chemotherapy regimens," depending "on chemotherapy dose and type, with worse results at higher doses" [10]. Reaching and holding that scalp temperature is what the cap and the clinic control; the drug and dose are not negotiable for hair reasons.

The scalp-metastasis question#

The concern is that cooling shields scalp tumor cells along with the follicles. A meta-analysis covering "1,959 cooling patients (mean 43.1 months follow-up) and 1,238 controls (mean 87.4 months)" [11] found "The incidence of scalp metastasis was 0.61% (95% CI 0.32-1.1%) with cooling versus 0.41% (95% CI 0.13-0.94%) without cooling (P = 0.43)" [11]. Controls were followed roughly twice as long [11], so the cooling data are less mature. Raise it with your oncologist.

The Regrowth Timeline and Texture Changes#

When regrowth starts and what to expect#

The anagen effluvium review gives the expected course: "Although it is reversible, and hair regrowth occurs after a delay of 1-3 months; sometimes it can lead to permanent alopecia" [1]. The source does not say when the clock starts; because each infusion injures the follicle again, it is reasonable to expect the delay to run from the last cycle rather than the first.

The FEC-plus-taxane cohort tracked what came back: "Any hair changes (e.g., thinned diameter, softer texture, curlier structure) were reported by 85.3% of the patients" [4]. That is the familiar "chemo curl," often with finer hair; the sources here give no timeline for texture returning to baseline. Age mattered for non-scalp hair: "The onset of eyebrows, eyelash, and body hair growth were significantly shorter in the premenopausal patients" [4]. Same-schedule photographs show slow early progress best; see the photo tracking guide.

Persistent Alopecia and Minoxidil#

Persistent chemotherapy-induced alopecia after docetaxel#

For a minority, hair does not fully return. Definitions vary: a docetaxel review says "Some patients experience persistent CIA (pCIA) when hair fails to recover within six months post-treatment" [13], while a genetic study defined severe pCIA as "lack of scalp hair recovery at grade 2 or higher 18+ months post-treatment" [12]. Frequency data are thinner than for acute loss. The scoping review reported that "pCIA occurred in up to 67% of patients treated with doxorubicin-based regimens" [3] and a high proportion after docetaxel combinations, though that estimate rests on weaker data [3]. An earlier review warned that "Permanent alopecia increasingly appears with both high-dose and standard regimens" [15], and a case series of "100 breast cancer survivors (99 women) with persistent alopecia" found "Taxane-containing chemotherapy was associated with more severe hair loss" [16].

Genetics may explain part of the variation: among "215 women with breast cancer treated with docetaxel-based chemotherapy (1.5-10 year follow-up)" [12], a regulatory variant in a drug-transporter gene showed a "combined odds ratio, 4.05; 95% CI, 2.46-6.67" [12] for pCIA. Not yet a clinical test.

Minoxidil for regrowth and for persistent loss#

The evidence for minoxidil is in recovery, not prevention: a review supports scalp cooling for prevention and 2% topical minoxidil as "a therapy for accelerating regrowth" [15]. "Twenty-two breast cancer patients participated in a double-blind randomized study comparing 2% minoxidil solution to placebo" [14], which showed "A statistically significant difference (favoring minoxidil) in the interval from maximal hair loss to first regrowth, shortening baldness duration by mean 50.2 days in the treatment group" [14], with "No significant adverse effects" [14]. The effect is on speed, not on whether hair returns.

For persistent alopecia the evidence is observational: in the survivor series, "Both topical and oral minoxidil, sometimes combined with antiandrogen therapy, were associated with an improvement in hair density" [16], and the authors concluded that the condition may be "at least partly reversible" with treatment [16]. None of the sources in this guide is a randomized trial of oral minoxidil after chemotherapy, and oral minoxidil has cardiovascular side effects of its own, which is one reason to involve the team that knows your full treatment history. Bring the option to your oncologist and a dermatologist who sees cancer survivors; do not start it on your own. The guides on minoxidil for women and oral minoxidil cover the drug's side effects.

Endocrine Therapy, Targeted Therapy, and Immunotherapy#

Tamoxifen and aromatase inhibitors cause milder, patterned thinning#

In a cohort of "112 breast cancer patients with endocrine therapy-induced alopecia" [17], "The condition was linked to aromatase inhibitors in 67% of cases and tamoxifen in 33%" [17], and "Severity was predominantly grade 1 (92%), resembling androgenetic alopecia patterns" [17]. This is diffuse thinning, not shafts breaking. "Following topical minoxidil treatment, moderate or significant improvement in alopecia was observed in 37 of 46 patients (80%)" [17].

Across "35 clinical trials involving 19,430 patients" [18], "Overall alopecia incidence ranged from 0-25%, with an aggregate rate of 4.4% (95% confidence interval: 3.3%-5.9%)" [18]; "Tamoxifen showed the highest incidence at 25.4% in one trial" [18], and "The relative risk compared to placebo was 12.88 (p<.001)" [18]. Real and drug-related, but far less frequent and less severe than taxane or anthracycline loss; the female pattern hair loss guide is relevant background. Do not stop endocrine therapy over hair thinning; ask your oncologist about a dermatology referral.

Targeted therapy and immunotherapy: the data are thin#

Published reviews of checkpoint-inhibitor side effects describe hair loss only qualitatively; no reliable incidence figure for immunotherapy alone was found for this guide. One large trial shows why headline figures mislead: in the RUBY trial, "The most common adverse events included nausea (53.9% of the patients in the dostarlimab group and 45.9% of those in the placebo group), alopecia (53.5% and 50.0%), and fatigue (51.9% and 54.5%)" [19]. Both arms received carboplatin and paclitaxel, so the near-identical alopecia rates reflect the taxane, not the checkpoint inhibitor.

See a dermatologist if hair has not returned within the window your oncologist expected, if loss is patchy, or if the scalp is red, painful, scaly, or scarred; the scarring alopecia guide explains those signs. If hair loss is affecting your mood, the emotional support guide lists resources.

Frequently Asked Questions#

Related Resources#

• Telogen Effluvium: Causes and Recovery Timeline
• Hair Loss After Surgery, Illness or Anesthesia
• Minoxidil for Women: Complete Guide
• Oral Minoxidil for Hair Loss: Evidence-Based Review
• Tracking Hair Loss Progress: Photo Guide
• When to See a Dermatologist for Hair Loss: Red Flags
• Emotional Impact of Hair Loss: Support Guide for Women